DOCSLIB.ORG

Differential Roles of the Two Major Endocannabinoid Hydrolyzing Enzymes in Cannabinoid Receptor Tolerance and Somatic Withdrawal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2010 Differential roles of the two major endocannabinoid hydrolyzing enzymes in cannabinoid receptor tolerance and somatic withdrawal Joel Schlosburg Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medical Pharmacology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2107 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Joel E. Schlosburg 2010 All Rights Reserved i DIFFERENTIAL ROLES OF THE TWO MAJOR ENDOCANNABINOID HYDROLYZING ENZYMES IN CANNABINOID RECEPTOR TOLERANCE AND SOMATIC WITHDRAWAL A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University. By Joel E. Schlosburg Bachelors of Science, Chemical Engineering, Rensselaer Polytechnic Institute, 2005 Bachelors of Science, Psychology, Rensselaer Polytechnic Institute, 2005 Director: Dr. Aron Lichtman, Ph.D. Professor, Department of Pharmacology & Toxicology Virginia Commonwealth University Richmond, Virginia May 2010 ACKNOWLEDGEMENTS While it was certainly not conventional for a chemical engineer to suddenly decide to become a drug abuse researcher, my experience and training during my time here at VCU was everything I hoped for…and none of the dangerous and unpleasant chemical plants I would’ve enjoyed otherwise. First and foremost, I have to thank my advisor, Dr. Aron Lichtman. I honestly don’t know why I somehow ended up in his laboratory over any other, if only by mixture of prodding and random choice, and yet I don’t know how I could’ve been quite as successful as I was without him. He knew exactly when to guide my sometimes wild and random exuberance for doing everything, knew when to introduce new folds into my work to keep things challenging and hectic, and occasionally gave me an insanely long leash that few might, trusting me to come back with something worthwhile. He taught me not how to work hard, but work efficiently, and to always understand your outcomes on both a numerical and conceptual level. Thanks are also in order to the original members of my graduate committee: Dr. Guy Cabral & Dr. Hamid Akbarali. Special thanks to Dr. Dan Conrad & Dr. Imad Damaj for stepping in on short notice and unusual circumstances to become integral influences in my work. It’s been a crazy and evolving group, but they have made sure to keep me focused on getting to this point even when I was busy skipping a few steps, and bringing their “A game” to make sure I got a thorough humbling just when I thought I had my act together. Additional acknowledgement must be extended to Dr. Laura Sim-Selley & Dr. Dana Selley, who literally had the confidence in me to give me the keys to the castle, and allowed me free reign of their lab any time I needed. Their guidance and assistance, and insistence that I get my hands dirty whenever possible (quite literally) has made me a far greater and complete scientist with an incredible breadth of skills to apply towards my future endeavors. It’s not a very well-kept secret that I got into this to teach and mentor, and if research is accomplished it’s a pleasant consequence. So this goes to Brittany, Divya, Roberta, Dolores, Ashley, Darby, and all those I had a chance to teach and mentor in some way while I was here. I also must acknowledge all those Lichtman lab members who have influenced and broadened my appreciation of the work I do: Drs. Andy Thorpe, Sree Pattipati, Floride Niyuhire, Steve Varvel, Laura Wise, John Harloe, Troy DeLong, & Rehab Abdullah. To Carlotta and Kelly, you guys kept me on my toes all the time, and otherwise always entertained with endless random conversation passing the time through what could sometimes be endless monotony. To Scott, well…ours is a bond that few can explain and few states legally condone. But seriously, you’re presence always kept my time interesting, and added some unusual twists to my day. To Sean, I wish you all the luck. You are taking on what can only be considered a project that I could never get the courage to take a risk on, and the rewards are potentially fantastic. To Lamont, you’re my boy, and I cannot thank you enough for always trying to keep me (just if only occasionally) focused on life outside the lab, and keeping me surrounded by other people. This place probably wouldn’t be a very bearable place without having you around. To Steve, I don’t know whether I’ve been teaching you a thing or two or the other way around all this time, but we seem to work well together on a rather scary level. Lord knows I cannot wait until the day comes when we meet again at some random conference and instantly captivate a room with the most inane conversation those stiffs have ever seen. Just try to keep it even a little clean. To my folks, this is obviously just another testament to the rather extreme and extraordinary efforts you went to make sure I was always able to be on top and go as far as I could. The teaching me algebra on a magnetic desk at age 5, fighting for every bus line that didn’t exist before, hybrid classes that were never really conceived…you guys will enjoy your retirement with a pair of kids with graduate degrees and highly successful careers for your efforts, despite all the bumps along the way. To my brother, it’s not always been the most congenial relationship, but we always did things together when it really mattered, and hopefully that’ll always be the way things are. To Mandy, I cannot imagine a more caring and nurturing sister-in- law…makes me wonder how different life would’ve been growing up with a few more girls around. To Jen, thanks for always being the female sensibility and outside influence I needed when my life got a little too focused in lab. To my rugrat nephew Ethan, you keep me inspired to do great things and be a great success for you to look toward some day. With the wonderful people around you, you’ll be ready for all you own success one day, a good start might be getting to the point you can remotely read and understand this paper in the least bit. Good luck with that! And to the future little niece to be named later (Riley), I hope to be successful enough to be around much more by your preschool years, finger crossed. Finally, this is in memoriam to a couple of gigantic influences in my life for very different reasons. To Dr. Billy Martin, you steered me to VCU, to cannabinoids, to Aron, and to a rather unusual project from little more than a random observation. It was an honor to unofficially be your last mentee, and your shadow looms large over my launch into the world of research. Your honesty and practical view the options in front of me brought incredible clarity to a confused kid with too many options and time in front of him. Lastly, to my grandmother (Nana), who passed just after my acceptance letter here arrived, you were the driving force for my greatness. Your pride and constant showing off of all my little accomplishments to all you knew, your need to make sure I always looked my best and put my best foot forward, and always taking my side whether I was right or not; it all gave me a reason to go for the next great accomplishment, and to do so in a way that impressed, and do so the way I wanted. I’m still going for it, and I’m still not done… TABLE OF CONTENTS List of Tables ....................................................................................................................................vi List of Figures ...................................................................................................................................vii List of Abbreviations ........................................................................................................................ix Abstract .............................................................................................................................................xii Introduction .......................................................................................................................................1 The discovery of cannabinoid ligands and receptors .............................................................2 Actions of cannabinoid receptors...........................................................................................3 The endocannabinoid system: ligands and regulatory pathways ...........................................5 Anandamide and fatty acid amide hydrolase inactivation .....................................................9 2-arachidonoylglycerol and monoacylglycerol lipase inactivation .......................................12 Tolerance and receptor adaptations following repeated cannabinoid administration............14 Physical withdrawal resulting from repeated exposure to cannabinoids ...............................16 Rational and Hypothesis ...................................................................................................................18 Methods..............................................................................................................................................22 Chapter 1: Endocannabinoid elevations in attenuation of THC physical withdrawal and potential for endocannabinoid induction
Recommended publications
  • 615 Neuroscience-Cayman-Bertin

    615 Neuroscience-Cayman-Bertin

    Thomas G. Brock, Ph.D. Introduction to Neuroscience In our first Biology classes, we learned that lipids form the membranes around cells. For many students, interests quickly moved to the intracellular constituents ‘that really matter’, or to how cells or systems work in health and disease. If there was further thought about lipids, it might have been limited to more personal issues, like an expanding waistline. It was easy to forget about lipids in the complexities of, say, Alzheimer’s Disease, where tau protein is hyperphosphorylated by a host of kinases before forming neurofibrillary tangles and amyloid precursor protein is processed by assorted secretases, ultimately aggregating to form neurodegenerating plaques. What possible role could lipids have in all this? After all, lipids just form the membranes around cells. Fortunately, neuroscientists study complex systems. Whether working at the molecular, cellular, or organismal level, the research focus always returns to the intricately interconnected bigger picture. Perhaps surprisingly, lipids keep emerging as part of the bigger picture. At least, the smaller lipids do. Many of the smaller lipids, including the cannabinoids and eicosanoids, act as paracrine hormones, modulating cell functions in a receptor-mediated fashion. In this sense, they are rather like the peptide hormones in their diversity and actions. In the neurosystem, this means that these signaling lipids determine if synapses fire or not, when cells differentiate or die, and whether tissues remain healthy or become inflamed. Returning to the question posed above about lipids in Alzheimer’s, these mediators have roles at many levels in the course of the disease, as presented in an article on page 42 of this catalog.
  • Modulation of Central Endocannabinoid System Results in Gastric Mucosal Protection in the Rat

    Modulation of Central Endocannabinoid System Results in Gastric Mucosal Protection in the Rat

    Modulation of central endocannabinoid system results in gastric mucosal protection in the rat Tóth, V.E.1, Fehér, Á.1, Németh, J.2, Gyertyán, I.3, Zádori, Z.S.1, Gyires K.1 1 Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., 1089 Budapest, Hungary; 2 Department of Pharmacology and Pharmacotherapy, University of Debrecen, Nagyerdei krt. 98., 4032 Debrecen, Hungary; 3 MTA-SE NAP B Cognitive Translational Behavioural Pharmacology Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad tér 4., 1089 Budapest, Hungary *Corresponding author: Klára Gyires Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad tér 4., 1089, Budapest, Hungary Phone: 36-1-210-4416, Fax: 36-1-210-4412 e-mail: [email protected] 1 Abstract Previous findings showed that inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), degrading enzymes of anandamide (2-AEA) and 2- arachidonoylglycerol (2-AG), reduced the nonsteroidal anti-inflammatory drug-induced gastric lesions. The present study aimed to investigate: i./whether central or peripheral mechanism play a major role in the gastroprotective effect of inhibitors of FAAH, MAGL and AEA uptake, ii./ which peripheral mechanism(s) may be responsible for mucosal protective effect of FAAH, MAGL and uptake inhibitors. Methods: Gastric mucosal damage was induced by acidified ethanol. Gastric motility was measured in anesthetized rats. Catalepsy and the body temperature were also evaluated. Mucosal calcitonin gene- related peptide (CGRP), somatostatin concentrations and superoxide dismutase (SOD) activity were measured. The compounds were injected intraperitoneally (i.p.) or intracerebroventricularly (i.c.v.). Results: 1. URB 597, JZL184 (inhibitors of FAAH and MAGL) and AM 404 (inhibitor of AEA uptake) decreased the mucosal lesions significantly given either i.c.v.
  • Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer

    Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer

    cancers Review Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer Viktoriia Cherkasova, Olga Kovalchuk * and Igor Kovalchuk * Department of Biological Sciences, University of Lethbridge, Lethbridge, AB T1K 7X8, Canada; [email protected] * Correspondence: [email protected] (O.K.); [email protected] (I.K.) Simple Summary: In recent years, multiple preclinical studies have shown that changes in endo- cannabinoid system signaling may have various effects on intestinal inflammation and colorectal cancer. However, not all tumors can respond to cannabinoid therapy in the same manner. Given that colorectal cancer is a heterogeneous disease with different genomic landscapes, experiments with cannabinoids should involve different molecular subtypes, emerging mutations, and various stages of the disease. We hope that this review can help researchers form a comprehensive understanding of cannabinoid interactions in colorectal cancer and intestinal bowel diseases. We believe that selecting a particular experimental model based on the disease’s genetic landscape is a crucial step in the drug discovery, which eventually may tremendously benefit patient’s treatment outcomes and bring us one step closer to individualized medicine. Abstract: Despite the multiple preventive measures and treatment options, colorectal cancer holds a significant place in the world’s disease and mortality rates. The development of novel therapy is in Citation: Cherkasova, V.; Kovalchuk, critical need, and based on recent experimental data, cannabinoids could become excellent candidates. O.; Kovalchuk, I. Cannabinoids and This review covered known experimental studies regarding the effects of cannabinoids on intestinal Endocannabinoid System Changes in inflammation and colorectal cancer. In our opinion, because colorectal cancer is a heterogeneous Intestinal Inflammation and disease with different genomic landscapes, the choice of cannabinoids for tumor prevention and Colorectal Cancer.
  • Targeting the Endocannabinoid System to Reduce Nociception

    Targeting the Endocannabinoid System to Reduce Nociception

    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2011 Targeting the endocannabinoid system to reduce nociception Lamont Booker Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medical Pharmacology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2419 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Targeting the Endocannabinoid System to Reduce Nociception A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University. By Lamont Booker Bachelor’s of Science, Fayetteville State University 2003 Master’s of Toxicology, North Carolina State University 2005 Director: Dr. Aron H. Lichtman, Professor, Pharmacology & Toxicology Virginia Commonwealth University Richmond, Virginia April 2011 Acknowledgements The author wishes to thank several people. I like to thank my advisor Dr. Aron Lichtman for taking a chance and allowing me to work under his guidance. He has been a great influence not only with project and research direction, but as an excellent example of what a mentor should be (always willing to listen, understanding the needs of each student/technician, and willing to provide a hand when available). Additionally, I like to thank all of my committee members (Drs. Galya Abdrakmanova, Francine Cabral, Sandra Welch, Mike Grotewiel) for your patience and willingness to participate as a member. Our term together has truly been memorable! I owe a special thanks to Sheryol Cox, and Dr.
  • S41467-020-19780-Z.Pdf

    S41467-020-19780-Z.Pdf

    ARTICLE https://doi.org/10.1038/s41467-020-19780-z OPEN Endocannabinoid signaling regulates the reinforcing and psychostimulant effects of ketamine in mice Wei Xu1,3, Hongchun Li1,3, Liang Wang1, Jiamei Zhang1, Chunqi Liu1, Xuemei Wan1, Xiaochong Liu1, Yiming Hu1, ✉ Qiyao Fang1, Yuanyuan Xiao1, Qian Bu1, Hongbo Wang2, Jingwei Tian2, Yinglan Zhao1 & Xiaobo Cen 1 The abuse potential of ketamine limits its clinical application, but the precise mechanism remains largely unclear. Here we discovered that ketamine significantly remodels the 1234567890():,; endocannabinoid-related lipidome and activates 2-arachidonoylglycerol (2-AG) signaling in the dorsal striatum (caudate nucleus and putamen, CPu) of mice. Elevated 2-AG in the CPu is essential for the psychostimulant and reinforcing effects of ketamine, whereas blockade of the cannabinoid CB1 receptor, a predominant 2-AG receptor, attenuates ketamine-induced remodeling of neuronal dendrite structure and neurobehaviors. Ketamine represses the transcription of the monoacylglycerol lipase (MAGL) gene by promoting the expression of PRDM5, a negative transcription factor of the MAGL gene, leading to increased 2-AG pro- duction. Genetic overexpression of MAGL or silencing of PRDM5 expression in the CPu robustly reduces 2-AG production and ketamine effects. Collectively, endocannabinoid signaling plays a critical role in mediating the psychostimulant and reinforcing properties of ketamine. 1 National Chengdu Center for Safety Evaluation of Drugs, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, 610041 Chengdu, People’s Republic of China. 2 Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, 264005 Yantai, People’s Republic of China.
  • Inhibition of Monoacylglycerol Lipase Reduces the Reinstatement Of

    Inhibition of Monoacylglycerol Lipase Reduces the Reinstatement Of

    International Journal of Neuropsychopharmacology (2019) 22(2): 165–172 doi:10.1093/ijnp/pyy086 Advance Access Publication: November 27, 2018 Regular Research Article regular research article Inhibition of Monoacylglycerol Lipase Reduces the Reinstatement of Methamphetamine-Seeking and Anxiety-Like Behaviors in Methamphetamine Self-Administered Rats Yoko Nawata, Taku Yamaguchi, Ryo Fukumori, Tsuneyuki Yamamoto Department of Pharmacology, Faculty of Pharmaceutical Science, Nagasaki International University, Nagasaki, Japan Correspondence: Tsuneyuki Yamamoto, PhD, Department of Pharmacology, Faculty of Pharmaceutical Science, Nagasaki International University, 2825–7 Huis Ten Bosch Sasebo, Nagasaki 859–3298, Japan ([email protected]). Abstract Background: Methamphetamine is a highly addictive psychostimulant with reinforcing properties. Our laboratory previously found that Δ8-tetrahydrocannabinol, an exogenous cannabinoid, suppressed the reinstatement of methamphetamine- seeking behavior. The purpose of this study was to determine whether the elevation of endocannabinoids modulates the reinstatement of methamphetamine-seeking behavior and emotional changes in methamphetamine self-administered rats. Methods: Rats were tested for the reinstatement of methamphetamine-seeking behavior following methamphetamine self- administration and extinction. The elevated plus-maze test was performed in methamphetamine self-administered rats during withdrawal. We investigated the effects of JZL184 and URB597, 2 inhibitors of endocannabinoid hydrolysis, on the reinstatement of methamphetamine-seeking and anxiety-like behaviors. Results: JZL184 (32 and 40 mg/kg, i.p.), an inhibitor of monoacylglycerol lipase, significantly attenuated both the cue- and stress-induced reinstatement of methamphetamine-seeking behavior. Furthermore, URB597 (3.2 and 10 mg/kg, i.p.), an inhibitor of fatty acid amide hydrolase, attenuated only cue-induced reinstatement. AM251, a cannabinoid CB1 receptor antagonist, antagonized the attenuation of cue-induced reinstatement by JZL184 but not URB597.
  • 2-Arachidonoylglycerol a Signaling Lipid with Manifold Actions in the Brain

    2-Arachidonoylglycerol a Signaling Lipid with Manifold Actions in the Brain

    Progress in Lipid Research 71 (2018) 1–17 Contents lists available at ScienceDirect Progress in Lipid Research journal homepage: www.elsevier.com/locate/plipres Review 2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain T ⁎ Marc P. Baggelaara,1, Mauro Maccarroneb,c,2, Mario van der Stelta, ,2 a Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands. b Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy c European Centre for Brain Research/IRCCS Santa Lucia Foundation, via del Fosso del Fiorano 65, 00143 Rome, Italy ABSTRACT 2-Arachidonoylglycerol (2-AG) is a signaling lipid in the central nervous system that is a key regulator of neurotransmitter release. 2-AG is an endocannabinoid that activates the cannabinoid CB1 receptor. It is involved in a wide array of (patho)physiological functions, such as emotion, cognition, energy balance, pain sensation and neuroinflammation. In this review, we describe the biosynthetic and metabolic pathways of 2-AG and how chemical and genetic perturbation of these pathways has led to insight in the biological role of this signaling lipid. Finally, we discuss the potential therapeutic benefits of modulating 2-AG levels in the brain. 1. Introduction [24–26], locomotor activity [27,28], learning and memory [29,30], epileptogenesis [31], neuroprotection [32], pain sensation [33], mood 2-Arachidonoylglycerol (2-AG) is one of the most extensively stu- [34,35], stress and anxiety [36], addiction [37], and reward [38]. CB1 died monoacylglycerols. It acts as an important signal and as an in- receptor signaling is tightly regulated by biosynthetic and catabolic termediate in lipid metabolism [1,2].
  • The Selective Reversible FAAH Inhibitor, SSR411298, Restores The

    The Selective Reversible FAAH Inhibitor, SSR411298, Restores The

    www.nature.com/scientificreports OPEN The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive Received: 22 September 2017 Accepted: 26 January 2018 behaviors to acute and chronic Published: xx xx xxxx stress in rodents Guy Griebel1, Jeanne Stemmelin2, Mati Lopez-Grancha3, Valérie Fauchey3, Franck Slowinski4, Philippe Pichat5, Gihad Dargazanli4, Ahmed Abouabdellah4, Caroline Cohen6 & Olivier E. Bergis7 Enhancing endogenous cannabinoid (eCB) signaling has been considered as a potential strategy for the treatment of stress-related conditions. Fatty acid amide hydrolase (FAAH) represents the primary degradation enzyme of the eCB anandamide (AEA), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). This study describes a potent reversible FAAH inhibitor, SSR411298. The drug acts as a selective inhibitor of FAAH, which potently increases hippocampal levels of AEA, OEA and PEA in mice. Despite elevating eCB levels, SSR411298 did not mimic the interoceptive state or produce the behavioral side-efects (memory defcit and motor impairment) evoked by direct-acting cannabinoids. When SSR411298 was tested in models of anxiety, it only exerted clear anxiolytic-like efects under highly aversive conditions following exposure to a traumatic event, such as in the mouse defense test battery and social defeat procedure. Results from experiments in models of depression showed that SSR411298 produced robust antidepressant-like activity in the rat forced-swimming test and in the mouse chronic mild stress model, restoring notably the development of inadequate coping responses to chronic stress. This preclinical profle positions SSR411298 as a promising drug candidate to treat diseases such as post-traumatic stress disorder, which involves the development of maladaptive behaviors. Te endocannabinoid (eCB) system is formed by two G protein-coupled receptors, CB1 and CB2, and their main transmitters, N-arachidonoylethanolamine (anandamide; AEA) and 2-arachidonoyglycerol (2-AG)1.
  • Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System

    Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System

    International Journal of Molecular Sciences Review Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System Ana Lago-Fernandez , Sara Zarzo-Arias, Nadine Jagerovic * and Paula Morales * Medicinal Chemistry Institute, Spanish Research Council, Juan de la Cierva 3, 28006 Madrid, Spain; [email protected] (A.L.-F.); [email protected] (S.Z.-A.) * Correspondence: [email protected] (N.J.); [email protected] (P.M.); Tel.: +34-91-562-2900 (P.M.) Abstract: Cannabinoids have shown to exert their therapeutic actions through a variety of targets. These include not only the canonical cannabinoid receptors CB1R and CB2R but also related orphan G protein-coupled receptors (GPCRs), ligand-gated ion channels, transient receptor potential (TRP) channels, metabolic enzymes, and nuclear receptors. In this review, we aim to summarize reported compounds exhibiting their therapeutic effects upon the modulation of CB1R and/or CB2R and the nuclear peroxisome proliferator-activated receptors (PPARs). Concomitant actions at CBRs and PPARα or PPARγ subtypes have shown to mediate antiobesity, analgesic, antitumoral, or neuroprotective properties of a variety of phytogenic, endogenous, and synthetic cannabinoids. The relevance of this multitargeting mechanism of action has been analyzed in the context of diverse pathologies. Synergistic effects triggered by combinatorial treatment with ligands that modulate the aforementioned targets have also been considered. This literature overview provides structural and pharmacological insights for the further development of dual cannabinoids for specific disorders. Citation: Lago-Fernandez, A.; Zarzo-Arias, S.; Jagerovic, N.; Keywords: PPAR; cannabinoids; CB1R; CB2R; FAAH; multitarget; endocannabinoid system Morales, P. Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System.
  • Cannabinoid Interventions for PTSD: Where to Next?

    Cannabinoid Interventions for PTSD: Where to Next?

    Accepted Manuscript Cannabinoid interventions for PTSD: Where to next? Luke Ney, Allison Matthews, Raimondo Bruno, Kim Felmingham PII: S0278-5846(19)30034-X DOI: https://doi.org/10.1016/j.pnpbp.2019.03.017 Reference: PNP 9622 To appear in: Progress in Neuropsychopharmacology & Biological Psychiatry Received date: 14 January 2019 Revised date: 20 March 2019 Accepted date: 29 March 2019 Please cite this article as: L. Ney, A. Matthews, R. Bruno, et al., Cannabinoid interventions for PTSD: Where to next?, Progress in Neuropsychopharmacology & Biological Psychiatry, https://doi.org/10.1016/j.pnpbp.2019.03.017 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT 1 Cannabinoid interventions for PTSD: Where to next? Luke Ney1, Allison Matthews1, Raimondo Bruno1 and Kim Felmingham2 1School of Psychology, University of Tasmania, Australia 2School of Psychological Sciences, University of Melbourne, Australia ACCEPTED MANUSCRIPT ACCEPTED MANUSCRIPT 2 Abstract Cannabinoids are a promising method for pharmacological treatment of post- traumatic stress disorder (PTSD). Despite considerable research devoted to the effect of cannabinoid modulation on PTSD symptomology, there is not a currently agreed way by which the cannabinoid system should be targeted in humans. In this review, we present an overview of recent research identifying neurological pathways by which different cannabinoid-based treatments may exert their effects on PTSD symptomology.
  • Synthetic Cannabinoids (60 Substances) A) Classical Cannabinoid

    Synthetic Cannabinoids (60 Substances) A) Classical Cannabinoid

    Synthetic cannabinoids (60 substances) a) Classical cannabinoid OH H OH H O Common name Chemical name CAS number Molecular Formula HU-210 3-(1,1’-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1- Synonym: 112830-95-2 C H O hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol 25 38 3 11-Hydroxy-Δ-8-THC-DMH b) Nonclassical cannabinoids OH OH R2 R3 R4 R1 CAS Molecular Common name Chemical name R1 R2 R3 R4 number Formula rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methyloctan- 2- yl) CP-47,497 70434-82-1 C H O CH H H H phenol 21 34 2 3 rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methylheptan- 2- yl) CP-47,497-C6 - C H O H H H H phenol 20 32 2 CP-47,497-C8 rel-2- [(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methylnonan- 2- yl) 70434-92-3 C H O C H H H H Synonym: Cannabicyclohexanol phenol 22 36 2 2 5 CAS Molecular Common name Chemical name R1 R2 R3 R4 number Formula rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methyldecan- 2- yl) CP-47,497-C9 - C H O C H H H H phenol 23 38 2 3 7 rel-2- ((1 R,2 R,5 R)-5- hydroxy- 2- (3- hydroxypropyl)cyclohexyl)- 3-hydroxy CP-55,940 83003-12-7 C H O CH H H 5-(2- methyloctan- 2- yl)phenol 24 40 3 3 propyl rel-2- [(1 S,3 R)-3- hydroxy-5,5-dimethylcyclohexyl]- 5- (2- Dimethyl CP-47,497-C8 - C H O C H CH CH H methylnonan-2- yl)phenol 24 40 2 2 5 3 3 c) Aminoalkylindoles i) Naphthoylindoles 1' R R3' R2' O N CAS Molecular Common name Chemical name R1’ R2’ R3’ number Formula [1-[(1- methyl- 2- piperidinyl)methyl]- 1 H-indol- 3- yl]- 1- 1-methyl-2- AM-1220 137642-54-7 C H N O H H naphthalenyl-methanone 26 26 2 piperidinyl
  • Assessment of Anandamide's Pharmacological Effects in Mice Deficient of Both Fatty Acid Amide Hydrolase and Cannabinoid CB1 Receptors

    Assessment of Anandamide's Pharmacological Effects in Mice Deficient of Both Fatty Acid Amide Hydrolase and Cannabinoid CB1 Receptors

    European Journal of Pharmacology 557 (2007) 44–48 www.elsevier.com/locate/ejphar Short communication Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors Laura E. Wise a, Christopher C. Shelton a, Benjamin F. Cravatt b, ⁎ Billy R. Martin a, Aron H. Lichtman a, a Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298-0613, United States b The Skaggs Institute for Chemical Biology and Departments of Cell Biology and Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Rd. La Jolla, CA 92037, United States Received 12 September 2006; received in revised form 2 November 2006; accepted 6 November 2006 Available online 10 November 2006 Abstract In the present study, we investigated whether anandamide produces its behavioral effects through a cannabinoid CB1 receptor mechanism of action. The behavioral effects of anandamide were evaluated in mice that lacked both fatty acid amide hydrolase (FAAH) and cannabinoid CB1 receptors (DKO) as compared to FAAH (−/−), cannabinoid CB1 (−/−), and wild type mice. Anandamide produced analgesia, catalepsy, and hypothermia in FAAH (−/−) mice, but failed to elicit any of these effects in the other three genotypes. In contrast, anandamide decreased locomotor behavior regardless of genotype, suggesting the involvement of multiple mechanisms of action, including its products of degradation. These findings indicate that the cannabinoid CB1 receptor is the predominant target mediating anandamide's behavioral effects. © 2006 Elsevier B.V. All rights reserved. Keywords: Cannabinoid CB1 receptor; FAAH [Fatty acid amide hydrolase]; N-arachidonoyl ethanolamine (anandamide); Pain; Analgesia; Marijuana 1.